Where does Ocuphire Pharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ocuphire Pharma, Inc. ranks #24,925 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ocuphire Pharma, Inc. hold?

Ocuphire Pharma, Inc. holds 11 US utility patents granted between 2019 and 2024, spanning 3 technology areas.

What is Ocuphire Pharma, Inc.'s Innovation Score?

Ocuphire Pharma, Inc. has an Innovation Score of 36.7 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ocuphire Pharma, Inc. focus on?

Ocuphire Pharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 11 patents, ranking #1,740 of 6,058 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Ocuphire Pharma, Inc.'s patent grant rate increasing or decreasing?

Ocuphire Pharma, Inc.'s recent grant velocity is +900% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Ocuphire Pharma, Inc.'s patents?

Ocuphire Pharma, Inc.'s patents average 23.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ocuphire Pharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Ocuphire Pharma, Inc.

USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ocuphire ranks #24,925 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 3 technology areas.

#24,925
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.7/100): 23.3
avg claims per patent: +900%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24925 · US Corporation #24,925 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,925/49,997
PHOTO-FINISH ObsEva
CPC-NARROW A61P · 3 areas
INNOV-THIN 36.7/100
CLAIMS-DENSE 23.3 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +900% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ObsEva S.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ocuphire’s 36.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (23%) Velocity 8.0 pts (22%) Breadth 6.1 pts (17%) Claim depth 14.0 pts (38%)

Qualcomm Incorporated · highest

85
Ocuphire Pharma · this assignee

37
3D Lighting… · lowest

7

What this shows Ocuphire's Innovation Score is 36.7/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ocuphire?

Each dot is one of Ocuphire’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ocuphire’s own 23.3 claims/patent is ABOVE the 11.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ocuphire vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ocuphire's grants concentrate

Ocuphire Pharma, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2019. By volume, Ocuphire sits between Otto Engineering, Inc. and Ohemo Life Sciences, Inc..

Ocuphire's three-year grant acceleration

Ocuphire Pharma, Inc. shows 6 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Otto Engineering

11
Outdoor Element

11
Obseva

11
Oculis Operations…

11
Océ Printing Syst…

11
Oerlikon Friction…

11
Ogura &

11
Ohemo Life Scienc…

11
Ocuphire Pharma ◀

11

What this shows Ocuphire holds 11 patents at rank #24,932, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ocuphire

By rank, the assignees closest to #24,932 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ocuphire's primary technology class.

Ocuphire's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Ocuphire Pharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	9.1%
2020	1	9.1%
2021	3	27.3%
2022	1	9.1%
2023	3	27.3%
2024	2	18.2%

Which technologies does Ocuphire Pharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07D - Heterocyclic Compounds 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ocuphire Pharma, Inc.'s patent record in context - here's where to go next.

Ocuphire Pharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #24,925 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ocuphire Pharma, Inc. against Otto Engineering, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.